Navigation Links
FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
Date:12/10/2009

the choice of the adult FAP patient population, selection of cohort size, the dosing regimen, and duration of treatment. The trial is designed to determine safety and tolerability of CEQ508, starting with a dose-escalation phase in which patients will be given one of four escalating concentrations of the drug, contingent upon safety monitoring. This initial part of the clinical trial is expected to take approximately six months. Next, following a safety review, the trial plan calls for a stable-dose phase in which additional patients will receive the highest safe dose. The FDA will permit daily dosing of 18 or more patients for 28 days. A key readout and secondary objective of the trial includes analysis of biomarker beta-catenin expression changes in the gastrointestinal tract of patients determined from biopsy samples obtained prior to taking the drug and at the end of the dosing period.

Cequent's Vice President of Drug Development, Alison Silva, commented, "I want to commend the reviewers at CBER who have been very responsive, providing critical feedback immediately following our submission and throughout the application process. They worked with us so that we could address their questions quickly and effectively to reach a successful conclusion by our action date."

With the FDA approval of Cequent's clinical-trial protocol now in hand, the company has begun working with the proposed clinical center to obtain the necessary institutional approvals. Cequent expects to begin the Phase I clinical trial during the first quarter of 2010 at the Fred Hutchinson Cancer Research Center in Seattle, Washington, part of the Fred Hutchinson/University of Washington Cancer Consortium. The Cancer Consortium maintains a registry of FAP patients and is also one of 40 National Cancer Institute-designated comprehensive cancer centers nationwide. Gideon Steinbach, M.D., Ph.D., is slated to be the principal investigator (PI) of the Cequent trial. Dr. Steinbach is
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
2. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
3. U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
4. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
5. Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
6. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
7. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
8. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
11. Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 2015 Olympus, a global technology leader ... and surgical procedures, among other core businesses, announced ... equipment at no additional charge. Olympus is the ... of guarantee. The service became available to customers ... year. Olympus, Full Service Agreement ...
(Date:6/30/2015)... , June 30, 2015 First Choice Wellness ... the Astanza Duality and is the only clinic in ... professional tattoo removal treatments. The practice has recently expanded ... brand to showcase their focus in the procedure. ... better results, faster ink clearance, and superior service. ...
(Date:6/30/2015)... June 30, 2015 Oramed Pharmaceuticals ... clinical-stage pharmaceutical Company focused on the development of oral ... has been screened in the Company,s Phase IIb trial ... study will be performed under the active Investigational New ... and Drug Administration (FDA). The Phase IIb ...
Breaking Medicine Technology:Olympus Introduces Industry-First Next-Day Product Replacement Guarantee for Surgical Business 2Olympus Introduces Industry-First Next-Day Product Replacement Guarantee for Surgical Business 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 2Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 3
... July 21, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... of medical devices worldwide, today announced that it will report ... 2011 after the U.S. market closes on August 8, 2011. ... AM on August 9, 2011 U.S. Eastern Time (8:00 PM ...
... advances impacting both individual lives and public health in ... announced the 2011 final candidates for the 5th annual ... the technical, scientific and clinical research skills necessary to ... industry,s highest accolade. Final candidates for the ...
Cached Medicine Technology:Mindray to Report Second Quarter 2011 Financial Results on August 8, 2011 22011 Prix Galien USA Final Candidates Announced: Competing for Best Biotechnology Product and Best Pharmaceutical Agent 2
(Date:6/30/2015)... ... 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier of premium ... new CEO, Mr. Darold Francis. The changes will help enhance the company’s focus on ... have come to know and respect for over eight years. , “I am thrilled ...
(Date:6/30/2015)... York, NY (PRWEB) , ... June 30, 2015 , ... The U.S. Women's National ... in mid-August. The first match will be on Sunday, August 16th at Heinz Field ... Costa Rica will meet again at Finley Stadium in Chattanooga, TN. , The USA WNT ...
(Date:6/30/2015)... ... June 30, 2015 , ... Red Hot & Blue ... recent online poll at http://scoutology.com/novaburgerwars and was selected as “Best BBQ” in ... August 2015. , Red Hot & Blue President Randy McCann said, “Everyone knows Red ...
(Date:6/30/2015)... ... 30, 2015 , ... Independence Day weekend is more than just fireworks to ... off of July as National Hot Dog Month. Americans are expected to eat more ... of the year and enough to stretch from Washington D.C. to Los Angeles more ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... Northwest ENT and Allergy Center . , Dr. Antunes is ... reconstructive, sinus and ear procedures. In addition to performing cosmetic and reconstructive surgery ...
Breaking Medicine News(10 mins):Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:USA vs. Costa Rica Tickets at Heinz Field in Pittsburgh and Finley Stadium in Chattanooga: Ticket Down Slashes Presale Ticket Prices for Costa Rica vs. USA WNT 2Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 2Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 3Health News:Biggest Hot Dog Weekend of the Year to Kick Off National Hot Dog Month 2Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 2Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 3
... In line with the International Women’s Day celebrations, an ... Apollo hospitals. Ms. J. Jayalalitha, State Chief Minister, inaugurated ... ,The health care center would cater to ... sub-acute and chronic problems. Of the health problems that ...
... and Prevention sudden infant death syndrome (SIDS) is the primary ... 1. Statistics show that about 3,000 infants die each year ... unknown. Jan-Marino Ramirez, an associate professor of organismal biology and ... study would provide an important clue that could lead to ...
... study claims that calcium intake was not associated with weight ... published in the American Journal of Clinical Nutrition. ... enrolled in the Health Professionals Follow-up Study were taken as ... between total calcium intake from diet and supplements and changes ...
... elderly man was ordered to vacate the hospital bed that he had ... court passed out ruling because this man refused to leave the hospital ... , Mr. Justice Wilkie gave the 72-year-old man 14 days to leave ... was also asked to pay ?10,000 towards the legal bill run up ...
... another Herceptin refusal case in the UK, a 10-year-old girl whose ... from her MP in order to ensure that her // mother ... treated with Herceptin, but Shropshire Primary Care Trust has not obliged ... Paterson, the MP of the region has received the letter written ...
... and with no new case cropped up in the past ... dishes on board.// ,The usual favourites like cheese ... sighted on many flights Wednesday morning. ,"Many of ... the list," said Sunil Taneja, director business development, TajSats catering ...
Cached Medicine News:Health News:Disturbance in Serotonin Levels Result in Reduced Gasping In Kids with SIDS 2
Reagent Basin, 60mL, 5/Box...
For use with 8 channel pipets....
96 channel Parallel dispenser using Positive Air Displacement Technology...
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
Medicine Products: